What is Citius Pharmaceuticals, Inc. (CTXR) stock price today?

Citius Pharmaceuticals, Inc. (CTXR) is currently trading at $0.50, up 2.19% today.

What is CTXR P/E ratio?

Citius Pharmaceuticals, Inc.'s P/E ratio is -0.25. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CTXR return on equity (ROE)?

Citius Pharmaceuticals, Inc.'s return on equity (ROE) is -67.15%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Citius Pharmaceuticals, Inc.'s market cap?

Citius Pharmaceuticals, Inc. has a market capitalization of $13.71M.

NASDAQ · Biotechnology

Citius Pharmaceuticals, Inc. (CTXR) Stock

$0.50 +2.19% NASDAQ: CTXR Healthcare

Valuation

Metric	Value
Price	$0.50
Market Cap	$13.71M
P/E Ratio	-0.25
P/B Ratio	0.20
P/S Ratio	2.01
EPS (TTM)	$2.82
52-Week High	$2.19
52-Week Low	$0.47
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-67.15%
ROA	-32.53%
ROCE	-67.75%
Gross Margin	37.36%
Operating Margin	-10.41%
Net Margin	-651.27%
Debt/Equity	0.11
Current Ratio	0.62

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-24.0M	$-33.0M	$-37.0M	$-42.0M	$-39.0M
Net Profit	$-23.0M	$-34.0M	$-33.0M	$-39.0M	$-37.0M
EPS	$-5.64	$-5.75	$-5.57	$-5.97	$-3.38
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$142.0M	$114.0M	$104.0M	$117.0M	$131.0M
Total Liabilities	$10.0M	$11.0M	$12.0M	$43.0M	$53.0M
Cash	$70.0M	$42.0M	$26.0M	$3.0M	$4.0M
Borrowings	$1.0M	$1.0M	$0	$0	$2.0M

Latest News

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies PR Newswire · Jun 1, 2026 Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR Newswire · May 26, 2026 Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? Insider Monkey · May 24, 2026 Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · May 15, 2026 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · May 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-24.0M	$-28.0M	$-29.0M	$-28.0M	$-27.0M
Investing Cash Flow	$-80.0M	$0	$0	$-5.0M	$-6.0M
Financing Cash Flow	$31.0M	$0	$0	$-4.0M	$0
Net Cash Flow	$56.0M	$-28.0M	$-15.0M	$-23.0M	$1.0M
Free Cash Flow	$-64.0M	$-28.0M	$-29.0M	$-28.0M	$-27.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.08
FCF Yield	-244.25%
Quick Ratio	0.40
Interest Coverage	-88.28
Return 1Y	-67.42%
Return 3Y	-98.21%
Return 5Y	-98.90%

Ownership

Insiders Held1.80%

Institutions Held3.63%

Institutions Float Held3.70%

Institutional Holder	Shares	Report Date
Geode Capital Management, LLC	246,158	2026-03-31
Vanguard Capital Management LLC	167,738	2026-03-31
Vanguard Fiduciary Trust Co	77,755	2026-03-31
Blackrock Inc.	69,851	2026-03-31
HRT Financial LP	60,332	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADTX	$0.01	-77.22%	-0.01	$318	0.00%
APLMApollomics Inc.	$21.50	-1.29%	-2.84	$47.22M	0.00%
ATHAAthira Pharma, Inc.	$6.75	-6.12%	-0.28	$26.62M	0.00%
CRISCuris, Inc.	$0.67	-5.38%	-0.06	$1.31M	0.00%
DAREDare Bioscience, Inc.	$0.77	+0.16%	-0.98	$11.59M	0.00%

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is led by CEO Leonard L. Mazur, employs 23 people, headquartered in US, publicly traded since 2014.

Citius Pharmaceuticals, Inc. (CTXR) stock trades at $0.50 with a market capitalization of $13.71M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of 0.20, price-to-sales of 2.01. Over the past 52 weeks the stock has ranged between $0.47 and $2.19, and currently trades 77.2% below its 52-week high.

On profitability, Citius Pharmaceuticals, Inc. generates a return on equity (ROE) of -67.15%, return on capital employed of -67.75%, an operating margin of -10.41%, a net profit margin of -651.27%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides